PBYI News 73.37 Puma Biotechnology (PBYI)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Puma Biotechnology (PBYI) 73.37 $PBYI

The Biggest Biotech Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 15, 5:30PM CDT
Another tough week for the biotechnology industry overshadowed impressive clinical results from several companies. Alkermes scored a big win in a difficult indication. Puma Biotechnology announced a high probability of success with its single...

NYSE stocks posting largest percentage decreases
AP - Tue Apr 15, 12:55PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at 1 p.m.:

Notable Two Hundred Day Moving Average Cross - PBYI
MarketNewsVideo.com - Mon Apr 14, 3:22PM CDT
In trading on Monday, shares of Puma Biotechnology, Inc. crossed below their 200 day moving average of $74.19, changing hands as low as $71.12 per share.

3 Biotech Stocks Falling Like a Knife: Puma Biotechnology, MacroGenics, and Aratana Therapeutics
George Budwell, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Biotech stocks have been in near free-fall the past month, with the iShares Nasdaq Biotechnology Index dropping a noteworthy 15.4%. While this could be part of a general market correction, such a dramatic decline may indicate deeper issues with...

3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 9:00AM CDT
Plenty of health-care stocks hit major headwinds this week. Few were blown away like these three, though. One of this week's major losers disappointed investors with mid-stage clinical results. Another had some big news that didn't seem to move...

Here's What's Behind Puma's Crash
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 11, 5:30PM CDT
Alan Auerbach, the former CEO of Cougar Biotechnology -- the company that developed Johnson & Johnson 's widely successful Zytiga prostate cancer drug -- hopes he has another blockbuster potential drug on his hands at Puma Biotechnology . ...

Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS
PR Newswire - Thu Apr 10, 11:28AM CDT
Today, Analysts Review released its analysts' notes regarding Puma Biotechnology, Inc. (NYSE: PBYI), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), INSYS Therapeutics, Inc. (NASDAQ: INSY), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and VIVUS Inc (NYSE: ESC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:45AM CDT
Puma Biotechnology has seen negative consensus estimates for the current quarter along with a significant decline in its share price for the past month

NYSE stocks posting largest volume increases
AP - Mon Apr 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:

Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL
Business Wire - Mon Apr 07, 12:31PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced the presentation of positive results from the Phase II clinical trial of Puma's investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY 2 TRIAL) in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, California. The presentation entitled "Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL" was presented today at the session entitled "Clinical Trials Symposium: Biomarker Driven Clinical Trials."
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 356

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 371

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 150

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 347

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 309

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 238

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 243

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Cryptocurrency Market Analysis: Bitcoin Hits New Low

Updated Category News Views 197

Cryptocurrency Market Update On Friday morning, cryptocurrency enthusiasts awoke to disappointing news: Bitcoin has fallen below $109,000, marking a significant decline for the leading digital asset. This marks the first time Bitcoin has dipped below this level since early September, raising questions about the current state and future of digital currencies. Key...

Continue Reading
Hagar hf. Expands Operations with P/F SMS Acquisition

Updated Category News Views 239

Hagar hf. Expands Its Business Footprint Recently, a significant announcement was made about Hagar hf. enhancing its business strategy through the acquisition of P/F SMS, a prominent supermarket chain in the Faroe Islands. This strategic move was publicized on a notable occasion, indicating the completion of a conditional agreement that allows Hagar hf. to fully acquire...

Continue Reading
Santander Achieves Impressive 12% Net Profit Growth in Q3

Updated Category News Views 238

Santander's Robust Net Profit Growth in Q3 Spain's Santander has announced an impressive 12% increase in net profit for the third quarter of 2023, underscoring the effectiveness of its retail operations. This remarkable performance has positioned the bank as one of the strongest contenders in the euro zone banking sector. Financial Highlights for Q3 In the latest...

Continue Reading
DBM Global Secures $220 Million Credit Facility for Growth

Updated Category News Views 318

DBM Global Inc. Enters Amended Credit Facility Agreement DBM Global Inc. (OTC Markets: DBMG) has recently made headlines by securing an amended and restated credit agreement that amounts to a significant total of $220 million. This financial maneuver comprises an $85 million term loan alongside a $135 million revolving credit facility, which aims to address existing debt...

Continue Reading
Projected Growth of Industrial Safety Market to USD 12.39 Billion

Updated Category News Views 82

Overview of the Industrial Safety Market Growth The Industrial Safety Market is experiencing remarkable growth, expected to expand from USD 6.74 billion in 2023 to a substantial USD 12.39 billion by 2032. This notable surge is attributed to a compound annual growth rate (CAGR) of 7%, reflecting an increased emphasis on safety within various industrial sectors. Key Factors...

Continue Reading